AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.
Not Applicable
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 529
- Registration Number
- NCT02336607
A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers Bioequivalence or Bioavailability Study
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2016-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT02322749
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo for terbutaline sulphate
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 95
- Registration Number
- NCT02322788
- Locations
- 🇸🇪
Research Site, Lund, Sweden
Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: BenralizumabBiological: Placebo
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 211
- Registration Number
- NCT02322775
- Locations
- 🇸🇰
Research Site, Zilina, Slovakia
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15992
- Registration Number
- NCT02322762
- Locations
- 🇦🇪
Research Site, Dubai, United Arab Emirates
An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).
Completed
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT02321046
- Locations
- 🇷🇺
Research Site, Yuzhno-Sakhalinsk, Russian Federation
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Phase 2
Completed
- Conditions
- Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
- Interventions
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 267
- Registration Number
- NCT02319044
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients
Phase 1
Completed
- Conditions
- Gout and Asymptomatic Hyperuricemia
- Interventions
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 110
- Registration Number
- NCT02317861
- Locations
- 🇯🇵
Research Site, Fukuoka-shi, Japan
China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients
Completed
- Conditions
- Stress-related Mucosal Disease (SRMD)Stress Ulcers
- First Posted Date
- 2014-12-15
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1416
- Registration Number
- NCT02316990
- Locations
- 🇨🇳
Research Site, Hangzhou, Zhejiang, China
Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Procedure: Pharmacokinetic sampling - AZD9291Drug: AZD9291 tablet dosingProcedure: Pharmacokinetic sampling - rosuvastatinProcedure: Pharmacokinetic sampling - AZ5140 and AZ7550
- First Posted Date
- 2014-12-15
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT02317016
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom